Pharmacogenomic testing: Relevance in medical practice

Pharmacogenomic testing: Relevance in medical practice
Why drugs work in some patients but not in others
JOSEPH P. KITZMILLER, MD, PhD
+ Author Affiliations
Department of Pharmacology, Division of Clinical Trials, College of Medicine, The Ohio State University, Columbus, OH
↵ADDRESS: Joseph P. Kitzmiller, MD, PhD, Department of Pharmacology, The Ohio State University, 5072C Graves Hall, 333 West 10th Avenue, Columbus, OH 43210; e-mail joseph.kitzmiller@osumc.edu.


DAVID K. GROEN, MD
+ Author Affiliations
Department of Pharmacology, Division of Clinical Trials, College of Medicine, The Ohio State University, Columbus, OH


MITCH A. PHELPS, PhD
+ Author Affiliations
Division of Pharmaceutics Resources, College of Pharmacy, The Ohio State University, Columbus, OH

WOLFGANG SADEE, Dr rer nat
+ Author Affiliations
Chairman, Department of Pharmacology; Director, Program in Pharmacogenomics, College of Medicine, The Ohio State University, Columbus, OH


Abstract
Genetics may account for much of the variability in our patients’ responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. It also discusses the future role of pharmacogenomic testing in medicine.


full-text:
Pharmacogenomic testing: Relevance in medical practice